Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by RxSight, Inc. (NASDAQ:RXST) and certain of its officers and/or directors. The firm is encouraging shareholders who purchased RxSight securities prior to November 7, 2024, and continue to hold them, to join the investigation. The firm specializes in securities fraud class actions and shareholder derivative suits, and represents investors on a contingency fee basis.
RXST PE Ratio & Valuation, Is RXST Overvalued
Rxsight Inc (RXST) is currently categorized as undervalued, with a forward PS ratio of 1.90 compared to its five-year average of -17.26. Its fair price is estimated to be between $12.97 and $33.75, making it undervalued by 48.8% relative to its current price of $6.64. While the company's P/S ratio is slightly above the industry average, its negative revenue growth raises concerns about the sustainability of this premium.
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to hold a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time, with a webcast available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, including the Light Adjustable Lens system for customized vision after cataract surgery.
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against RxSight, Inc. (RXST) on behalf of investors who purchased securities prior to November 7, 2024, and continue to hold them. The investigation focuses on whether the company's officers and/or directors engaged in corporate wrongdoing. Investors are encouraged to contact the firm to learn more about the investigation and potentially assist.
RxSight to Participate in Annual Healthcare Conference
RxSight, Inc., an ophthalmic medical device company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to present and hold a fireside chat on April 16, 2026, at 8:00 a.m. Pacific Time, highlighting its innovative Light Adjustable Lens system. This participation aims to increase awareness of their technology among investors and industry peers.
RxSight management joins Needham virtual healthcare event Apr. 16
RxSight (NASDAQ: RXST) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, with management hosting a fireside chat at 8:00 a.m. PT. While this event signals ongoing investor engagement, historical data suggests that conference participation announcements typically result in modest stock movements compared to financial updates or leadership changes. Investors are advised to focus on the company's execution against 2026 guidance and future operational milestones rather than this presentation for significant market impact.
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to hold a fireside chat on April 16, 2026, at 8:00 a.m. Pacific Time, which will be accessible via webcast on the company's investor relations website. RxSight is an ophthalmic medical device company known for its Light Adjustable Lens system, which allows for post-surgery vision customization for cataract patients.
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website.
RXST SEC Filings - Rxsight, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Rxsight (RXST) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Stock Titan offers AI-powered summaries of these documents to highlight key points quickly. The recent filings cover topics such as board committee appointments, beneficial ownership disclosures from various entities, and reports on material events and insider trading activity.
Trading Systems Reacting to (RXST) Volatility
This article analyzes Rxsight Inc. (NASDAQ: RXST) volatility, highlighting weak sentiment across all horizons and suggesting a short bias due to an exceptional risk-reward setup. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with multi-timeframe signal analysis. The piece also promotes accessing real-time signals and personalized alerts for ongoing analysis.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against RxSight, Inc. (NASDAQ:RXST) on behalf of investors who purchased shares before November 7, 2024, and continue to hold them. The investigation focuses on whether RxSight and its management engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to assist with the investigation, noting they represent investors on a contingency fee basis.
Vanguard realignment: RXST filings show 0 shares; subsidiaries report separately (RXST)
The Vanguard Group filed an amended Schedule 13G/A for RxSight Inc. (RXST), indicating they no longer beneficially own shares of the company. This change is due to an internal realignment, where Vanguard's subsidiaries will now report their holdings separately in accordance with SEC Release No. 34-39538. Vanguard now reports 0 shares beneficially owned, representing 0% of the class.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (RXST) securities. The firm encourages stockholders who purchased RxSight securities prior to November 7, 2024, and still hold them, to inquire about the securities investigation concerning alleged corporate wrongdoing by RxSight and its officers or directors. Investors can visit the firm's website or contact their client relations team for more information and to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by RxSight, Inc. (NASDAQ:RXST) and certain officers/directors. The firm is encouraging investors who purchased RxSight securities prior to November 7, 2024, and continue to hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and shareholder derivative suits, representing investors on a contingency fee basis.
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against RxSight, Inc. ("RxSight") concerning alleged corporate wrongdoing. The firm encourages shareholders who purchased RxSight securities before November 7, 2024, and still hold them, to contact them to assist with the investigation. This class action aims to recover investor capital and ensure corporate accountability.
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition
RxSight's investment outlook is evolving due to updated financial guidance and a change in CFO. The fair value estimate has slightly decreased from US$10.17 to US$10.06, reflecting new 2026 revenue guidance. While analysts remain largely neutral, they are refreshing their models to incorporate these recent developments and the implications of the new CFO appointment.
How Rxsight Inc. (RXST) Affects Rotational Strategy Timing
The article analyzes Rxsight Inc. (RXST) with a focus on its impact on rotational strategy timing, identifying weak sentiment across all horizons which supports a short bias. It details an exceptional risk-reward short setup targeting 41.4% downside. The analysis provides specific trading strategies, including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for different holding periods.
RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting
RxSight, Inc. filed an amended report (8-K/A) to provide updated details regarding the compensation of its new Chief Financial Officer, Mark Wilterding. The amendment specifies his cash sign-on bonus as $169,348.10, paid on March 13, 2026, and corrects the vesting schedule for his stock option. The vesting now states 25% on the first anniversary of January 11, 2026, with the remainder vesting monthly over the subsequent three years.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by RxSight, Inc. (NASDAQ:RXST). The law firm is encouraging investors who purchased RxSight securities before November 7, 2024, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased RxSight, Inc. (NASDAQ:RXST) securities before November 7, 2024. The investigation stems from concerns whether RxSight and its officers/directors engaged in corporate wrongdoing. The firm encourages affected stockholders to connect with them for more information or to assist in the investigation.
RXST Stock News Today | Earnings, Events & Price Alerts
This page provides a collection of recent news and events related to RXST stock, including earnings reports and financial guidance. Key updates include RxSight's Q4 2025 earnings report, 2026 financial guidance, and revenue expectations. The article also mentions their presentation at the J.P. Morgan Healthcare Conference.
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against RxSight, Inc. (NASDAQ: RXST) regarding corporate wrongdoing. The firm encourages investors who purchased RxSight securities before November 7, 2024, and still hold them, to contact them for more information and to assist in the investigation. The representation is on a contingency fee basis.
Meridiem Capital Partners LP Buys New Position in RxSight, Inc. $RXST
Meridiem Capital Partners LP has acquired a new stake of 174,014 shares in RxSight, Inc. (NASDAQ:RXST) during the third quarter, valued at approximately $1.56 million. This investment represents about 0.42% of RxSight's stock. Other institutional investors like Goldman Sachs have also increased their positions, though overall analyst sentiment for RXST is mixed, with an average "Reduce" rating and a target price of $9.78.
RxSight Inc Stock (ISIN: US78419L1008) Faces Analyst Pressure After Q4 Revenue Drop
RxSight Inc (ISIN: US78419L1008) experienced a 16% stock decline after reporting a 19% drop in Q4 revenue, primarily due to fewer placements of its Light Delivery Device. Analysts have responded with a 'Reduce' rating, reflecting concerns over decelerating growth and ongoing operating expenses. Despite strong gross margins on its light-adjustable lenses, the company faces increased execution risks in achieving its 2026 breakeven target.
Stifel cuts RxSight stock price target to $9 on revenue guidance
Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) to $9.00 from $10.00, maintaining a Hold rating due to the company's 2026 revenue guidance falling below Street expectations. Despite a strong Q4 2025 performance, the guidance for low-single-digit LAL volume growth suggests below-market expansion. Stifel notes that RxSight's stock valuation is becoming more attractive, especially after a 69% decline over the past year.
(RXST) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Rxsight Inc. (NASDAQ: RXST), highlighting a near-term neutral sentiment but suggesting a pause in mid and long-term weakness. It details several AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also emphasizes a favorable 184.5:1 risk-reward setup targeting a 53.9% gain.
Stifel cuts RxSight stock price target to $9 on revenue guidance
Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) shares to $9.00 from $10.00, maintaining a Hold rating due to the company's 2026 revenue guidance falling below Street expectations. Despite strong Q4 2025 earnings and revenue, the guidance implies low-single-digit year-over-year growth in LAL volumes, suggesting below-market growth. RxSight's stock has fallen 69% over the last year, although Needham reiterated a Buy rating with a $13.00 price target.
Stifel cuts RxSight stock price target to $9 on revenue guidance
Stifel lowered its price target on RxSight Inc. (NASDAQ:RXST) shares to $9.00 from $10.00, maintaining a Hold rating due to the company's initial 2026 revenue guidance falling below Street expectations. This guidance implies low-single-digit year-over-year growth in LAL volumes, suggesting below-market growth, despite a strong Q4 2025 performance. The firm noted that the stock appears undervalued at current levels, having significantly fallen over the past year.
RxSight Inc. (RXST) PT Lowered to $9 at Stifel After Prudent Guidance
Stifel analyst Tom Stephan has lowered the price target for RxSight Inc. (NASDAQ: RXST) from $10.00 to $9.00. This adjustment follows what is described as "prudent guidance" from the company. The article notes that this is premium content, requiring a subscription to StreetInsider.com to view the full details.
RxSight Inc. (RXST) PT Lowered to $9 at Stifel After Prudent Guidance
Stifel analyst Tom Stephan has lowered the price target for RxSight Inc. (NASDAQ: RXST) to $9.00 from $10.00. This adjustment comes after what the analyst describes as "prudent guidance" from the company. The full details of this analysis are available to premium subscribers of StreetInsider.com.
RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes
RxSight's Chief Customer Officer, Scott Gaines, reported transactions including the grant of 32,218 restricted stock units (RSUs) on February 27, 2026. On February 28, 2026, he acquired 6,261 common shares from RSU exercises and subsequently sold 2,580 shares at $7.61 each to cover tax obligations. Following these transactions, Gaines directly holds 14,848 shares of RxSight common stock.
RXST - Rxsight, Inc. Latest Stock News & Market Updates
This page provides news and analysis for RxSight, Inc. (RXST), an ophthalmic medical device company known for its Light Adjustable Lens system. It aggregates financial results, corporate developments, and commercial activities related to improving vision after cataract surgery. The article highlights the company's IPO details from 2021, including pricing and closing information.
RXST Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Rxsight, Inc. (RXST), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It highlights the company's financial health, scoring 43 out of 100, and discusses metrics like declining revenue, negative operating margin, and low earnings quality despite strong leverage and liquidity. The report suggests the company faces challenges in profitability and cash generation but has a strong balance sheet.
RxSight (RXST) COO granted 32,218 RSUs vesting through 2029
RxSight, Inc. Chief Operating Officer Ilya Goldshleger was granted 32,218 restricted stock units (RSUs) on February 27, 2026. These RSUs will vest in six equal installments between August 2026 and February 2029, contingent on his continued employment. This transaction was reported in a Form 4 SEC filing, indicating an acquisition of equity-based compensation for the COO.
RxSight (RXST) CEO granted 80,545 RSUs vesting through 2029
RxSight, Inc. (RXST) CEO Ronald M. Kurtz has been awarded 80,545 restricted stock units (RSUs) as reported in a recent SEC Form 4 filing. These RSUs represent a contingent right to receive one share of RxSight common stock each. The award is set to vest in six equal installments between August 2026 and February 2029, contingent upon Dr. Kurtz's continued service as per the company's 2021 Equity Incentive Plan.
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3%
Short interest in RxSight, Inc. (NASDAQ:RXST) increased by 29.3% in February, reaching 5,358,739 shares, which accounts for 14.4% of the company's stock. The short-interest ratio is currently 4.7 days based on average daily volume. Analyst consensus for RXST is a "Reduce" rating with an average price target of $9.89.
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
RxSight, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided its guidance for 2026. For the full year 2025, global sales were $156.5 million, a 4% decrease compared to the prior year, while gross profit increased to $103.0 million, or 65.8% of revenue. The company projects 2026 revenue to be between $120.0 million to $135.0 million, with a gross margin of 60% to 62%.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities who bought shares prior to November 7, 2024, and still hold them. The firm encourages these investors to inquire about a securities investigation into potential corporate wrongdoing by RxSight and its officers/directors. Investors can assist the investigation by visiting the firm's website or contacting their representatives.
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST
Artisan Partners Limited Partnership reduced its stake in RxSight, Inc. by 22.1% in the third quarter, selling 498,861 shares and now owning 1,753,683 shares valued at approximately $15.8 million, representing 4.26% of the company. Despite the reduction, other institutional investors have increased their holdings in RxSight. The company's stock was down 5.6% at $7.48, with a negative P/E ratio, and analysts have a cautious "Reduce" rating with a consensus price target of $9.89.
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
RxSight, Inc. announced it will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, which can be accessed via phone or a live webcast on their investor relations website. RxSight specializes in ophthalmic medical devices, notably the RxSight Light Adjustable Lens system for customizing vision after cataract surgery.
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript
RxSight, Inc. reported its Q4 and full-year 2025 earnings, with Q4 sales down 19% year-over-year due to lower Light Delivery Device (LDD) sales, though Light Adjustable Lens (LAL) sales remained stable, accounting for 86% of total revenue. The company provided 2026 revenue guidance of $120 million to $135 million, anticipating sequential improvements throughout the year and continued focus on international expansion and LAL technology innovation. Despite financial results below initial expectations, RxSight highlighted significant progress in 2025 and ongoing efforts to strengthen clinical expertise and market penetration for its adjustable intraocular lens technology.
RxSight Reports Fourth Quarter and Fiscal Year Financial Results
RxSight, Inc. announced its financial results for the fourth quarter and full year ending December 31, 2025, reporting a 4 percent decrease in global sales to $134.5 million for the full year. While light adjustable lens (LAL) revenue increased by 12 percent, this was offset by a significant 48 percent decrease in light delivery device (LDD) system sales. The company reported a net loss of $9.2 million for Q4 2025 and provided 2026 revenue guidance between $120.0 to $135.0 million.
RxSight (RXST) Loss Deepens In Q4 Results Reinforcing Bearish Profitability Narratives
RxSight (RXST) reported a deeper loss in Q4 2025, with revenue of US$32.6 million and a basic EPS loss of US$0.22, reinforcing concerns about its path to profitability. The company's trailing twelve-month revenue was US$134.5 million with a net loss of US$38.9 million, and revenue growth trails market expectations. Despite a P/S ratio higher than peers, RxSight remains unprofitable, leading to bearish narratives questioning its near-term profit potential, although bullish investors point to analyst price targets and future growth from premium lenses and international expansion.
What 5 Analyst Ratings Have To Say About RxSight
Five analysts have recently reviewed RxSight (NASDAQ: RXST), with a mix of bullish and indifferent perspectives. The average 12-month price target is set at $10.60, marking a 3.92% increase from the previous average. Despite the positive analyst sentiment, RxSight faces challenges in market capitalization, revenue growth, net margin, and returns on equity and assets, though it maintains a conservative debt-to-equity ratio.
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler
Piper Sandler has lowered its price target for RxSight (NASDAQ:RXST) to $10.00 from $11.00, maintaining a "neutral" rating on the stock. This adjustment comes as the stock experienced a roughly 14% drop in midday trading to $7.58, trading below its 50- and 200-day moving averages. Despite mixed analyst coverage, institutional ownership remains high at 78.78%, with a consensus target price of $9.78 and an overall "Reduce" rating from MarketBeat.
UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating
UBS has adjusted its price target for RxSight (RXST) shares to $9, an increase from the previous target of $8. The firm has concurrently maintained its "Neutral" rating on the medical technology company specializing in cataract surgery solutions. This update follows recent company activities, including earnings calls and CFO transitions.
RxSight (NASDAQ:RXST) Issues Earnings Results
RxSight (NASDAQ:RXST) recently reported Q4 2025 earnings, beating EPS estimates by $0.22 with ($0.03) EPS, but revenues declined 18.9% year-over-year. The company provided a cautious 2026 outlook, projecting revenues between $120M–$135M and a lower gross margin. Despite strong Light Adjustable Lens (LAL) momentum and clinical validation, analysts maintain a "Reduce" rating with an average price target of $9.78.
Eye lens maker RxSight tops 300,000 procedures, sets 2026 sales goals
RxSight, Inc. reported full-year 2025 financial results, with revenue down 4% to $134.5 million and a net loss of $38.9 million. Despite a 12% increase in Light Adjustable Lens (LAL) unit sales, overall revenue was impacted by a 48% decrease in Light Delivery Device (LDD) system sales. The company provided 2026 guidance, forecasting revenue between $120.0 million and $135.0 million, and announced that over 300,000 LAL procedures have been performed since launch.
RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations
RxSight, Inc. (RXST) reported a narrower-than-expected loss of $0.03 per share for the fourth quarter, significantly beating Zacks' estimate of a $0.23 loss, while also surpassing revenue expectations with $32.61 million. Despite these positive quarterly results and a consistent history of beating EPS and revenue forecasts, RxSight's stock has declined by 14.2% year-to-date, contrasting with the S&P 500's gain, and currently holds a Zacks Rank #4 (Sell) due to negative analyst estimate revisions. The company's future performance will depend on management's guidance and evolving analyst estimates, as the Medical - Instruments sector generally shows strong prospects.
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts
RxSight (RXST) reported stronger-than-expected Q4 2025 earnings, with an adjusted EPS of $0.03 against a forecasted loss of $0.35, and revenue of $32.6 million, surpassing expectations. Despite a 19% year-over-year decline in total sales due to lower Laser Delivery Device (LDD) sales, the company saw improved gross margins and stable Light Adjustable Lens (LAL) sales. RxSight provided 2026 revenue guidance between $120 million and $135 million, anticipating a decline due to LDD sales but expecting growth to rebound in the second half of the year.
